Marta Espanol-Rego
Overview
Explore the profile of Marta Espanol-Rego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado J, Bataller A, Ortiz-Maldonado V, Benitez-Ribas D, et al.
Cell Rep Med
. 2025 Feb;
:102026.
PMID: 39987917
No abstract available.
2.
Gomez-Puerta J, Monegal A, Ponce A, Peris P, Martinez-Cibrian N, Sarmiento-Monroy J, et al.
Semin Arthritis Rheum
. 2025 Jan;
71:152610.
PMID: 39754918
Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for hematological malignancies. However, its association with immune-related complications such as rheumatic complications, is not well defined....
3.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat J, Gonzalez-Calle V, Moreno D, et al.
Blood Adv
. 2024 Nov;
9(3):571-582.
PMID: 39602341
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in...
4.
Bachiller M, Barcelo-Genestar N, Rodriguez-Garcia A, Alserawan L, Dobano-Lopez C, Gimenez-Alejandre M, et al.
Mol Ther
. 2024 Nov;
33(1):317-335.
PMID: 39563035
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given...
5.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado J, Bataller A, Ortiz-Maldonado V, Benitez-Ribas D, et al.
Cell Rep Med
. 2024 Oct;
5(11):101803.
PMID: 39471818
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell...
6.
de Landazuri I, Oliver-Caldes A, Espanol-Rego M, Agullo C, Contreras M, Zabaleta A, et al.
Br J Haematol
. 2024 Jun;
205(4):1346-1355.
PMID: 38894496
Chimeric antigen receptor (CAR) T-cell therapies have increased the patients with relapsed/refractory multiple myeloma (RRMM) in whom standard electrophoretic techniques fail to detect the M-protein. Quantitative immunoprecipitation mass spectrometry (QIP-MS)...
7.
Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2085-2096.
PMID: 38466644
Purpose: B-cell maturation antigen (BCMA)-chimeric antigen receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated...
8.
Martinez-Cibrian N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, Cid J, Lozano M, et al.
Br J Haematol
. 2023 Oct;
204(2):525-533.
PMID: 37905734
Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial. Here we report updated outcomes of...
9.
Oliver-Caldes A, Gonzalez-Calle V, Cabanas V, Espanol-Rego M, Rodriguez-Otero P, Reguera J, et al.
Lancet Oncol
. 2023 Jul;
24(8):913-924.
PMID: 37414060
Background: Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. We aimed...
10.
Vidal-Robau N, Caballero G, Archilla I, Ladino A, Fernandez S, Ortiz-Maldonado V, et al.
Free Neuropathol
. 2023 Jun;
3.
PMID: 37284165
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for the treatment of refractory hematopoietic malignancies. Adverse events are common, and neurotoxicity is one of the most important. However,...